Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: fitzdad55 who wrote (3230)	2/22/2014 7:52:59 PM
From: tejek	Respond to of 4474

I think there is some personal enmity between Feuerstein and Berger that is partly coloring AF's view of Ariad. I've also had a chance to look at some of the literature on AP26113and it does seem to hold a great deal more promise than a drug with the pejorative description assigned to it by AF. Thanks for posting this clip of Dr. Camidge's presentation. When I did my initial DD on ARIA, I saw a number of positive comments about '113. That's why AF's careless dismissal of the drug surprised me. Clearly Camidge has a very different view.